5-Hydroxytryptamine in Psychiatry
A Spectrum of Ideas
1st Edition
Published on 21. February 1991
Book
Hardback
364 pages
978-0-19-262011-8 (ISBN)
Description
The field of research in 5-hydroxytryptamine has exploded into furious activity over the past decade and nowhere have the implications been more far reaching than in psychiatry. Thanks largely to the introduction of radioligand binding techniques, a bewildering variety of 5-hydroxytryptamine receptors has been revealed, and powerful new families of centrally-active drugs have emerged. The importance of these new discoveries for psychiatric practice can hardly be exaggerated. To mention but one example, our understanding, and with it the treatment, of obsessive-compulsive disorder has been transformed in a very few years. The excitement continues, and almost daily, some important new insight, usually drug led, alters our whole perception of psychiatric illness. Due to this activity, the CINP chose 5-hydroxytryptamine and Psychiatry as the topic for its first President's Workshop.
The CINP is an international neuropharmacological organization renowned for its massive, comprehensive, and prestigious biennial congress. It recently decided to complement these with a different type of gathering, a small brain-storming meeting, dominated by a free-flowing discussion. The record of this first President's Workshop is recorded here. The contributors were all hand-picked, and are active researchers with a distinguished track record. They have all contributed substantially to the burgeoning 5-hydroxytryptamine field. The free-ranging style of this volume and the many good ideas presented cannot fail to be of major interest to all who wish to keep abreast of this rapidly moving area of research.
The CINP is an international neuropharmacological organization renowned for its massive, comprehensive, and prestigious biennial congress. It recently decided to complement these with a different type of gathering, a small brain-storming meeting, dominated by a free-flowing discussion. The record of this first President's Workshop is recorded here. The contributors were all hand-picked, and are active researchers with a distinguished track record. They have all contributed substantially to the burgeoning 5-hydroxytryptamine field. The free-ranging style of this volume and the many good ideas presented cannot fail to be of major interest to all who wish to keep abreast of this rapidly moving area of research.
Reviews / Votes
`This is a pleasure to read. The book is well indexed and referenced and each chapter is followed by excellent summaries of the discussions that followed each presentation. This is a `must' for all medical libraries and will be invaluable for any clinical or basic psychopharmacologist who wishes to get up to date with this fascinating area of neurobiology.' Human PsychopharmacologyMore details
Language
English
Place of publication
Oxford
United Kingdom
Target group
College/higher education
Professional and scholarly
Illustrations
halftones, line drawings and tables throughout
Dimensions
Height: 241 mm
Width: 163 mm
Thickness: 26 mm
Weight
720 gr
ISBN-13
978-0-19-262011-8 (9780192620118)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Persons
Content
M. Sandler: Introduction; S. J. Peroutka & A. W. Schmidt: An overview of 5-hydroxytryptamine receptor families; D. L. Murphy: An overview of serotonin neurochemistry and neuroanatomy; M. B. H. Youdim: Milacemide: a neuropsychotropic glycine prodrug that potentiates serotonergic activity; P. C. Waldmeier & L. Maitre: The inactive enantiomer of a noradrenaline uptake blocker reduces 5-HT synthesis; H. Y. Meltzer & R. C. Arora: Platelet serotonin studies in affective disorders: evidence for a serotonergic abnormality?; V. Glover, J. Jarman, & M. Sandler: The role of 5-HT in migraine: disentangling the links with depression; G. F. Oxenkrug: The acute effect of monoamine oxidase inhibitors on serotonin conversion to melatonin; G. F. Oxenkrug, P. Requintina, I. M. McIntyre, & R. Davis: Stimulation of rat pineal melatonin synthesis by a single electroconvulsive shock; G. Racagni, D. Tinelli, E. Bianchi, N. Brunello, & J. Perez: cAMP-dependent binding proteins and endogenous phosphorylation after anti-depressant treatment; P. J. Cowen & I. M. Anderson: Abnormal 5-HT neuroendocrine function in depression: association or artefact?; J. Deakin: Experimental tests of the 5-HT imbalance theory of affective disturbance; D. S. Robinson: Antidepressant efficacy of 5-HTO 1A partial agonist drugs; J. J. Lopez-Ibor Jr, J. Saiz-Ruiz, L. Moral, I. Moreno, & R. Vinas: Neuroendocrine serotonergic challenges in clinical research; M. Briley & P. Chopin: Serotonin in anxiety: evidence from animal models; C. Curzon, G. A. Kennett, & P. Whitton: Anxiogenic effect of the 5-HTO1C agonist m - chlorophenylpiperazine; M. Palfreyman & J. H. Kehne: Does 5-hydroxytryptamine have a role in anxiety and the action of anxiolytics?; T. R. Insel: Serotonin in obsessive-compulsive disorder: a casual connection or more monomania about a major monoamine?; M. Linnoila: Monoamines, glucose metabolism, and impulse control; G. Curzon: 5-Hydroxytryptamine in the control of feeding and its possible implications for appetite disturbance; B. Guardiola-Lemaitre: d-Fenfluramine and animal models of eating disorders; C. G. Gottfries: Disturbance of the 5-hydroxytryptamine metabolism in ageing and in Alzheimer's and vascular dementias; M. G. Palfreyman, S. M. Sorenson, A. A. Carr, H. C. Cheng, & M. W. Dudley: 5-HTO3 receptor antagonists and their potential in psychiatric disorders; H. Y. Meltzer: Atypical antipsychotic drugs: the 5HTO2/DAO2 ratio; A. Carlsson: Closing remarks; Index.